A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia

被引：0
|
作者：
Goemans, Bianca F. [1 ]
Zwaan, Christian M. [2 ]
Reinhardt, Dirk [3 ]
Gibson, Brenda E. S. [4 ]
Hahlen, K. [2 ,5 ]
Kaspers, Gert Jan L. [1 ,5 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, NL-1081 HV Amsterdam, Netherlands
[2] Erasmus MC Sophia Childrens Hosp, Dept Pediat Hematol Oncol, Rotterdam, Netherlands
[3] AML BFM Study Grp, Hannover, Germany
[4] UK Childhood Leukaemia Working Party, London, England
[5] Dutch Childhood Oncol Grp, The Hague, Netherlands
来源：
HAEMATOLOGICA | 2006年 / 91卷 / 11期
关键词：
liposomal daunorubicin; pediatric acute leukemia; drug sensitivity; cardiotoxicity;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Anthracyclines are effective in the treatment of leukemia, but their use is limited because of cardiotoxicity. Liposomal daunorubicin (L-DNR) is potentially less cardiotoxic than daunorubicin (DNR). We compared in vitro cytotoxicity in pediatric acute leukemia samples and found no significant differences between cytotoxicity of DNR and L-DNR.
引用
收藏
页码：1573 / 1574
页数：2
相关论文
共 50 条
  • [41] Immobilized forms of daunorubicin in patients with acute leukemia
    Isaev, VG
    Garmaeva, TT
    Skorokhod, AA
    Parovichnikova, EN
    Tyurina, NG
    Kucher, RA
    Vitvitsky, VM
    Ataullakhanov, FI
    Savchenko, VG
    TERAPEVTICHESKII ARKHIV, 1999, 71 (10) : 32 - +
  • [42] ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OF TREATMENT BY DAUNORUBICIN
    BERNARD, J
    WEIL, M
    BOIRON, M
    JACQUILLAT, C
    FLANDRIN, G
    GEMON, MF
    BLOOD, 1973, 41 (04) : 489 - 496
  • [43] Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia
    Asghari, Hannah
    Lancet, Jeffrey
    LEUKEMIA & LYMPHOMA, 2020, 61 (06) : 1305 - 1312
  • [44] Phase I study of liposomal daunorubicin (daunoxome) in relapsed and refractory acute myeloid leukemia.
    Lerchenmüller, C
    Büchner, T
    Berdel, WE
    BLOOD, 1999, 94 (10) : 233B - 233B
  • [45] Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia
    Bewersdorf, Jan Philipp
    Goshua, George
    Patel, Kishan K.
    Shallis, Rory M.
    Podoltsev, Nikolai
    Huntington, Scott F.
    Zeidan, Amer M.
    BLOOD, 2021, 138
  • [46] Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia
    Bewersdorf, Jan Philipp
    Patel, Kishan K.
    Goshua, George
    Shallis, Rory M.
    Podoltsev, Nikolai A.
    Huntington, Scott F.
    Zeidan, Amer M.
    BLOOD, 2022, 139 (11) : 1766 - 1770
  • [47] Liposome encapsulated daunorubicin (daunoxome) for acute leukemia
    Ermacora, A
    Michieli, M
    Pea, F
    Visani, G
    Bucalossi, A
    Russo, D
    HAEMATOLOGICA, 2000, 85 (03) : 324 - 325
  • [48] DAUNORUBICIN THERAPY IN ADULT ACUTE LYMPHATIC LEUKEMIA
    BLOOMFIE.CD
    BRUNNING, RD
    KENNEDY, BJ
    CANCER, 1972, 30 (01) : 47 - +
  • [49] Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia
    Clavio, M
    Pierri, I
    Venturino, C
    Garrone, A
    Canepa, L
    Miglino, M
    Varaldo, R
    Ballerini, F
    Michelis, GL
    Balocco, M
    Abdall, N
    Gatto, S
    Gobbi, M
    LEUKEMIA & LYMPHOMA, 2004, 45 (12) : 2527 - 2530
  • [50] Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
    Murphy, Tracy
    Yee, Karen W. L.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (16) : 1765 - 1780
12345